Consumer health sits at a tricky intersection: it's healthcare, but the buyer is the end user, not an employer or insurance company. That changes everything about how these investors evaluate you. They're looking for consumer-grade engagement metrics—DAUs, retention curves, NPS—alongside clinical credibility. You need to prove people will actually use your product repeatedly, not just download it once after a doctor's recommendation. Many founders coming from traditional healthcare backgrounds underestimate how much these investors care about brand, design, and organic growth loops. If your pitch leans heavily on clinical efficacy without addressing why a consumer would choose you over doing nothing, you'll lose the room. The best consumer health investors have often backed DTC or consumer companies outside healthcare, so they pattern-match against Warby Parker as much as Livongo.

​

The business model question will come up fast: are you cash-pay, insurance-reimbursed, or employer-sponsored? Each path has different investors who specialize in it. Cash-pay consumer health (think Hims, Ro, Noom) requires proving willingness-to-pay and unit economics that work without subsidies—these investors want to see strong LTV:CAC ratios and evidence that your category isn't just a vitamin people cancel after three months. If you're going after insurance reimbursement or employer contracts, you'll need to show you understand the slower sales cycles and can articulate a path to payor ROI. One nuance worth knowing: many consumer health investors got burned in 2021-2022 backing companies with unsustainable CACs, so they're now hypersensitive to customer acquisition efficiency. Come prepared with cohort data and a realistic view of how you'll grow without lighting money on fire.